Experienced in Thrombocytopenia

Hawk J. Kim

Incheon, KR 
Experienced in Thrombocytopenia
Incheon, KR 
OverviewLocationsClinical Research

Overview

Hawk Kim practices in Incheon, Republic of Korea. Mr. Kim is rated as an Experienced expert by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Aplastic Anemia, Chronic Myelogenous Leukemia (CML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 93 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles in the study of Thrombocytopenia.

Gender
Male

Locations

Incheon, Republic of Korea
Other Locations
Ulsan, Republic of Korea
Seoul, Republic of Korea
Daegu, 702701, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy
A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy
Enrollment Status: Terminated
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: REGN7257
Study Phase: Phase 1
Phase 2 Study of Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission
Phase 2 Study of Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Procedure
Study Phase: Not Applicable
A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic Anemia
A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic Anemia
Enrollment Status: Terminated
Publish Date: July 28, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia
Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia
Enrollment Status: Unknown
Publish Date: July 24, 2018
Intervention Type: Drug
Study Drugs: Rituximab, Modified VPDL
Study Phase: Phase 2
View 3 Less Clinical Trials

93 Total Publications

Gene expression analysis of patients with chronic myeloid leukemia who discontinued tyrosine kinase inhibitor.
Gene expression analysis of patients with chronic myeloid leukemia who discontinued tyrosine kinase inhibitor.
Journal: Annals of hematology
Published: March 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kim's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 22 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile